HUTCHMED (NASDAQ:HCM) announced the initiation of a registrational Phase III clinical trial for HMPL-760, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor.
Biogen (NASDAQ:BIIB) and Eisai, today released new real-world findings from a massive U.S. claims analysis demonstrating high long-term persistence rates for patients receiving intravenous (IV) LEQEMBI® (lecanemab).
Nektar Therapeutics (NASDAQ:NKTR) will present Phase 2b clinical data for rezpegaldesleukin at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, the company announced.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its proprietary TALEN® gene-editing platform to develop next-generation immunotherapies, announced its financial and operational results for the fiscal year ended December 31, 2025.
Pelthos Therapeutics (NYSE:PTHS) reported its fourth-quarter and full-year 2025 financial results, highlighting a period of rapid commercial acceleration for its flagship product, ZELSUVMI™ (berdazimer gel, 10.3%).
Pfizer (NYSE:PFE) today announced positive topline results from its Phase 3 TALAPRO-3 study, evaluating the combination of TALZENNA® (talazoparib) and XTANDI® (enzalutamide).
Theravance Biopharma (NASDAQ:TBPH) on Thursday reported financial results for the fourth quarter and full year ended December 31, 2025, revealing a year of significant financial recovery tempered by a major strategic pivot.
NeurAxis (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for children and adults, announced its financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025.
Aveanna Healthcare Holdings (NASDAQ:AVAH) announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, reporting a period of accelerated growth and significant margin expansion.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.
DarioHealth (NASDAQ:DRIO) today announced its financial results for the fourth quarter and full year ended December 31, 2025, describing the period as a critical "foundation-building" year.
Evotec (NASDAQ:EVO) announced today that it will receive a $10 million milestone payment from Bristol Myers Squibb (NYSE:BMY) following the start of a Phase 1 clinical trial for BMS-986506.
